Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05721287 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults
A Phase 1 study of Pain and Acute Pain, sponsored by Sparian Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05721287: Completed Phase 1 study of Pain and Acute Pain, sponsored by Sparian Biosciences.
NCT05721287 is a Phase 1 study of Pain and Acute Pain that has completed, run by Sparian Biosciences. The registered enrollment target is 48 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05721287, a Phase 1 study of Pain and Acute Pain, has completed, sponsored by Sparian Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a single-center, double-blind, randomized placebo-controlled, adaptive, single ascending dose study.
Primary Outcome
Adverse events as assessed by electrocardiogram, vital signs, end-tidal carbon dioxide, oxygen saturation, physical examination, clinical laboratory tests, OAAS, C-SSRS, slit-lamp examination, gastrointestinal/esophageal assessment and concomitant medications
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SBS-1000
Study Locations (1)
Kansas
- Altasciences Clinical Kansas - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 1 |
What the finished NCT05721287 record still lists
NCT05721287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05721287 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT05721287 about?
NCT05721287 is a clinical study titled "A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults". This study will be a single-center, double-blind, randomized placebo-controlled, adaptive, single ascending dose study.
What is the current status of trial NCT05721287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-01-30. Estimated completion is 2023-08-30.
What conditions does trial NCT05721287 study?
This clinical trial studies the following conditions: Pain, Acute Pain.
What interventions are being tested in trial NCT05721287?
The interventions under investigation include: Placebo (DRUG), SBS-1000 (DRUG).
Who is sponsoring clinical trial NCT05721287?
This trial is sponsored by Sparian Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05721287 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05721287's enrollment target sits among peer trials
48 265th of 374 higher than 109 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
RECRUITING · Phase 1
-
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
RECRUITING · Phase 1
-
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Phase 1 Study of SBS-147 in Healthy Adults
RECRUITING · Phase 1
-
Patient Controlled Administration of Liquid Acetaminophen
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI